Intra-Cellular Therapies Inc
NASDAQ:ITCI

Watchlist Manager
Intra-Cellular Therapies Inc Logo
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Watchlist
Price: 131.87 USD -0.04% Market Closed
Market Cap: 14B USD

Intrinsic Value

The intrinsic value of one ITCI stock under the Base Case scenario is 93.97 USD. Compared to the current market price of 131.87 USD, Intra-Cellular Therapies Inc is Overvalued by 29%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ITCI Intrinsic Value
93.97 USD
Overvaluation 29%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Intra-Cellular Therapies Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about ITCI?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is ITCI valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Intra-Cellular Therapies Inc.

Explain Valuation
Compare ITCI to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Heightened reliance on CAPLYTA leaves the firm vulnerable if commercial uptake underperforms — with almost all revenues riding on a single product, any shift in physician prescribing habits or unexpected regulatory snags could sharply impact top-line results.

Competition from well-established antipsychotics and newer treatments may constrain CAPLYTA’s market share — entrenched pharmaceutical players with broader sales networks and deeper resources could aggressively defend their schizophrenia and bipolar depression therapies, limiting Intra-Cellular’s room to grow.

Expanding into other indications and advancing early-stage pipelines strains capital resources — the firm’s ongoing R&D efforts involve significant up-front costs, and any pipeline disappointment could force hefty additional fundraising or dilute existing shareholders.

Bull Theses

CAPLYTA’s strong efficacy-benign side effect profile in schizophrenia and bipolar depression positions it as a potential best-in-class therapy — positive feedback from both patients and clinicians could accelerate market adoption and boost revenue growth.

Expansion into adjunctive uses and new indications provides a long runway — clinical trials exploring CAPLYTA’s potential in major depressive disorder and other psychiatric conditions could diversify revenue sources and reduce reliance on a single label.

Early-stage PDE1 inhibitor portfolio may unlock substantial new market opportunities beyond psychiatry — if pivotal trials confirm efficacy in areas such as heart failure or other central nervous system disorders, Intra-Cellular could secure lucrative avenues of growth.

Show More Less
How do you feel about ITCI?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Intra-Cellular Therapies Inc

Current Assets 1.3B
Cash & Short-Term Investments 1B
Receivables 166.5m
Other Current Assets 139.8m
Non-Current Assets 59.5m
PP&E 14.9m
Other Non-Current Assets 44.7m
Current Liabilities 205.7m
Accounts Payable 26.1m
Accrued Liabilities 179.6m
Non-Current Liabilities 12.7m
Other Non-Current Liabilities 12.7m
Efficiency

Free Cash Flow Analysis
Intra-Cellular Therapies Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Intra-Cellular Therapies Inc

Revenue
680.9m USD
Cost of Revenue
-57m USD
Gross Profit
623.9m USD
Operating Expenses
-740.6m USD
Operating Income
-116.7m USD
Other Expenses
42m USD
Net Income
-74.7m USD
Fundamental Scores

ITCI Profitability Score
Profitability Due Diligence

Intra-Cellular Therapies Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
Exceptional Gross Margin
ROE is Increasing
Strong 3Y Average Gross Margin
31/100
Profitability
Score

Intra-Cellular Therapies Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

ITCI Solvency Score
Solvency Due Diligence

Intra-Cellular Therapies Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Intra-Cellular Therapies Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ITCI Price Targets Summary
Intra-Cellular Therapies Inc

There are no price targets for ITCI.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Intra-Cellular Therapies Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ITCI is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

ITCI Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one ITCI stock?

The intrinsic value of one ITCI stock under the Base Case scenario is 93.97 USD.

Is ITCI stock undervalued or overvalued?

Compared to the current market price of 131.87 USD, Intra-Cellular Therapies Inc is Overvalued by 29%.

Back to Top